(Q39796888)

14 September 2017

title

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies (English)

1 reference

14 September 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

7

Nicola Gökbuget

0 references

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

14 September 2017

5

Richard A Larson

1 reference

14 September 2017

Anthony S Stein

2

1 reference

14 September 2017

Ralf C Bargou

3

1 reference

14 September 2017

Carlos Grande Garcia

4

1 reference

14 September 2017

Matthias Stelljes

6

1 reference

14 September 2017

Nicola Gökbuget

7

1 reference

14 September 2017

Gerhard Zugmaier

8

1 reference

14 September 2017

Jonathan E Benjamin

9

1 reference

14 September 2017

Alicia Zhang

10

1 reference

14 September 2017

Catherine Jia

11

1 reference

14 September 2017

Max S Topp

12

1 reference

14 September 2017

language of work or name

English

0 references

publication date

3 May 2016

1 reference

14 September 2017

1 reference

14 September 2017

volume

122

1 reference

14 September 2017

issue

14

1 reference

14 September 2017

page(s)

2178-2185

1 reference

Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

The challenges of managing older patients with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

How I treat older patients with ALL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Review of survival analyses published in cancer journals

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Treatment of elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Acute lymphoblastic leukemia: older patients and newer drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30031

7 January 2021

https://api.fatcat.wiki/v0/release/p32ex3omtbbqxgud5uonbblbby

Identifiers

1 reference

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_p32ex3omtbbqxgud5uonbblbby

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p32ex3omtbbqxgud5uonbblbby

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/p32ex3omtbbqxgud5uonbblbby

1 reference

30 July 2022